One report found that treatment of SLE with BAFF/APRIL inhibitor significantly improved the SLE responder index and safely decreased flares of severe disease relative to placebo plus standard SLE therapy [20]. This evidence concerns the gene TNFSF13B and systemic lupus erythematosus.